Eli Lilly stock rises on FDA nod, strong weight-loss results
Eli Lilly (LLY) rose for a sixth straight day Thursday, defying pressure from Trump GLP-1 pricing plan after upbeat FDA developments and new obesity drug data. The FDA granted priority status for Orforglipron, which showed 20% weight loss in a Phase 2 trial. Bank of America called the pricing deal a good tradeoff, reaffirming its $950 target as retail bullish.